ASX cannabis share Althea has jumped 535% in less than a year

The Althea Group Holdings Ltd (ASX:AGH) share price has been on fire since its IPO. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been yet another positive day of trade for the Althea Group Holdings Ltd (ASX: AGH) share price.

In afternoon trade the cannabis company's shares are up a sizeable 10.5% to a new all-time high of $1.27.

This latest gain means that Althea's shares have now gained a remarkable 535% since listing on the ASX at 20 cents per share in September.

Why is the Althea share price on fire?

Investors have been snapping up the company's shares since its IPO thanks to a series of positive developments.

One major development was the receipt of key manufacture and export licences late last year which mean the company now has a full complement of Office of Drug Control cannabis licences.

Since then the company has seen its patient numbers grow at a very quick rate. In fact, the company reached its 1,000-patient milestone in Australia five months ahead of schedule.

But arguably the biggest development has been the company's successful expansion into the UK market.

In May the company announced the launch of Althea Concierge UK. This is a medical education platform, which was launched in Australia in September 2018, that provides medical education and clinical evidence for healthcare professionals looking to prescribe medicinal cannabis.

The platform supports Althea UK's entry to the market by streamlining the prescription process and facilitating patient referrals from primary care doctors to Althea UK specialist prescribers.

This led to the company receiving its first patient prescription for Althea medicinal cannabis in the UK last month.

And it is unlikely to be the last. Also announced last month was an agreement with independent scientific committee Drug Science.

According to the release, its UK-based business has furthered its relationship with Drug Science with the goal of increasing the number of patients that can be prescribed medical cannabis in the UK market.

This comes at a time when Drug Science is just about to launch Project TWENTY21, which is the UK's first national pilot for medical cannabis and aims to enrol 20,000 patients before the end of 2021. Althea looks set to benefit from the pilot as it has been selected to supply, on commercial terms, its range of products to Project TWENTY21.

Things haven't been quite so positive for rival AusCann Group Holdings Ltd (ASX: AC8). A lack of meaningful developments has led to its shares shedding 40% of their value since the start of the year.

Should you invest $1,000 in Australia And New Zealand Banking Group right now?

Before you buy Australia And New Zealand Banking Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Australia And New Zealand Banking Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors were in the mood for buying this Tuesday.

Read more »

Miner looking at a tablet.
Share Gainers

Up 93% since April should I still buy Boss Energy shares now?

Boss Energy shares, the most shorted on the ASX, have almost doubled in value in one month. Now what?

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

Why BHP, Catapult, Life360, and Ridley shares are charging higher today

These shares are having a strong session. But why?

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Why are WiseTech shares up 7% today?

Investors can't get enough of WiseTech stock right now.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Guess how much $10,000 invested in Zip shares on 7 April is worth today!

The rebound in the Zip share price since 7 April has been nothing short of remarkable.

Read more »

Rising share price chart.
Share Gainers

Why Core Lithium, Goodman, GQG, and Macquarie shares are pushing higher today

These shares are starting the week in a positive fashion. But why?

Read more »

Happy woman working on a laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant end to the trading week for investors this Friday.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why Chrysos, GQG Partners, Macquarie, and Webjet shares are storming higher today

These shares are ending the week on a positive note. But why?

Read more »